Liraglutide
Diabetes
Phase 3Active
Key Facts
About Biocon
Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from a garage startup into Asia's premier biotechnology enterprise with a focus on affordable healthcare solutions. The company operates through three key subsidiaries: Biocon Biologics (biosimilars), Biocon Pharma (generics), and Syngene (research services), serving patients in over 120 countries. Biocon has established itself as a pioneer in insulin manufacturing and biosimilar development, with multiple products approved by stringent regulatory authorities including FDA and EMA.
View full company profileTherapeutic Areas
Other Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Toujeo | Sanofi | Commercial |
| Lantus | Sanofi | Commercial |
| Semglee (insulin glargine biosimilar) | Viatris | Approved |
| Semglee (Insulin Glargine) | Biocon | Approved |
| Insulin Aspart | Biocon | Phase 3 |
| MK-1293 (insulin glargine biosimilar) | Organon | Approved/Filed |
| Insulin Glargine (Biosimilar) | Gulf Pharmaceutical Industries | Approved/Commercial |
| CYAPO913 | FibroBiologics | Discovery |